Method for the treatment of Dravet syndrome
AssigneesKatholieke Universiteit Leuven, University Hospital Antwerp
InventorsBerten Ceulemens, Lieven Lagae
Life of this patent
Estimating the term…
Abstract
A method of treating and/or preventing Dravet Syndrome in a patient such as a patient previously diagnosed with Dravet Syndrome, by administering an effective dose of fenfluramine or its pharmaceutically acceptable salt to that patient. Dravet Syndrome patients are typically children under the age of 18 and are treated at a preferred dose of less than about 0.5 to about 0.01 mg/kg/day.
Claims6
A method of stimulating 5-HT receptors in the brain of a patient diagnosed with Dravet syndrome, comprising:
- administering to the patient 0.2 mg/kg/day of fenfluramine or a pharmaceutically acceptable salt thereof;
- and
- administering to the patient an effective dose of stiripentol or a pharmaceutically acceptable salt thereof;
- whereby 5-HT receptors are stimulated and wherein the 5-HT receptor is in a family of receptors selected from the group consisting of 5-HT1, 5-HT2, 5-HT3, 5-HT4, 5-HT5, 5-HT6, and 5-HT7.
A method of stimulating 5-HT receptors in the brain of a patient diagnosed with Dravet syndrome, comprising:
- administering to the patient an effective dose of fenfluramine or a pharmaceutically acceptable salt thereof administered in a dose of 0.5 mg/kg/day to 0.2 mg/kg/day to the patient;
- and
- administering to the patient an effective dose of stiripentol or a pharmaceutically acceptable salt thereof;
- whereby 5-HT receptors are stimulated.
Dependencies are inferred from the claim text.